PharmExec7d
FDA Approves Soleno Therapeutics’ Vykat XR for Hyperphagia in Patients with Prader-Willi Syndrome
Approval of Vykat XR marks the first treatment indicated for hyperphagia in patients with Prader-Willi syndrome.
PANTHERx® Rare Selected by Soleno Therapeutics for the Distribution of VYKAT™ XR
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...
Yahoo Finance8d
Soleno Therapeutics Announces U.S. FDA Approval of VYKAT(TM) XR to Treat Hyperphagia in Prader-Willi Syndrome
Soleno expects VYKAT XR to be available in the U.S. beginning in April 2025. “The approval of VYKAT XR is a significant ...
PMLive7d
FDA approves Soleno’s Vykat XR as first treatment for hyperphagia in Prader-Willi syndrome
The US Food and Drug Administration (FDA) has approved Soleno Therapeutics’ Vykat XR (diazoxide choline) extended-release ...
BioSpace7d
Soleno Wins First FDA Approval for Hyperphagia in Prader-Willi Syndrome
Vykat XR is specifically indicated to address hyperphagia, or the abnormally strong sensation of hunger, which often leads to ...
Fierce Pharma7d
Soleno breaks through with FDA nod for Prader-Willi syndrome treatment Vykat XR
Since 2000, when the FDA approved recombinant human growth hormone (rhGH) for those with the rare genetic disorder ...
Soleno Therapeutics announces FDA approval of VYKAT XR to treat hyperphagia
Soleno Therapeutics (SLNO) “announced that the FDA has approved VYKAT XR, diazoxide choline, extended-release tablets, previously referred to ...
Pharmabiz5d
US FDA approves Soleno Therapeutics’ Vykat XR to treat hyperphagia in Prader-Willi syndrome
US FDA approves Soleno Therapeutics’ Vykat XR to treat hyperphagia in Prader-Willi syndrome: Redwood City, California Saturday, March 29, 2025, 18:00 Hrs [IST] Soleno Therapeuti ...
Investing4d
Soleno Therapeutics’ SWOT analysis: FDA approval boosts rare disease stock
This outcome represents a best-case scenario for Soleno, as it aligns with expectations and provides a strong foundation for the drug’s commercial launch. VYKAT XR is set to enter the U.S ...